SCHEMBL2766462

SCHEMBL2766462

Nc1nnc(-c2ccncc2)o1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 2/20 0.74
TP53 P04637 1/20 0.74
NOTUM Q6P988 2/20 0.69
KDM4E B2RXH2 9/20 0.64
DGAT1 O75907 1/20 0.64
NPC1 O15118 7/20 0.63
RAB9A P51151 7/20 0.63
ATAD2 Q6PL18 2/20 0.63
CA1 P00915 1/20 0.55
CA2 P00918 1/20 0.55
HSD17B10 Q99714 4/20 0.53
USP2 O75604 1/20 0.52
CYP2C19 P33261 3/20 0.50
CYP1A2 P05177 2/20 0.50
KMT2A Q03164 3/20 0.49
ALDH1A1 P00352 3/20 0.49
HPGD P15428 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
MEN1 O00255 2/20 0.49
CYP3A4 P08684 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4883712 0.85 PKM (1.00) PKMTP53KDM4ENPC1RAB9A
SCHEMBL4876686 0.83 NPC1 (0.79) PKMTP53NOTUMKDM4EDGAT1
SCHEMBL3979 0.82 NOTUM (1.00) NOTUMKDM4EDGAT1NPC1RAB9A
SCHEMBL26673871 0.82 NPC1 (0.78) PKMTP53NOTUMKDM4EDGAT1
SCHEMBL9612006 0.81 PKM (0.90) PKMTP53KDM4ENPC1RAB9A
SCHEMBL11965041 0.81 PKM (0.90) PKMTP53KDM4ENPC1RAB9A
Ammonia Solution, Strong SCHEMBL16238468 0.80 NOTUM (0.96) NOTUMKDM4EDGAT1NPC1RAB9A
SCHEMBL1500576 0.78 NOTUM (0.64) PKMTP53NOTUMKDM4EDGAT1
SCHEMBL20767009 0.78 NPC1 (0.72) TP53NOTUMKDM4EDGAT1NPC1
SCHEMBL1143348 0.78 KDM4E (1.00) TP53NOTUMKDM4EDGAT1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117877625-A Virtual screening method for inhibitor MPB with human cyclooxygenase 2 as target and inhibitor thereof 重庆医科大学国际体外诊断研究院 2024-04-12 CN disclosed
US-10604494-B2 Acylated N-(1 ,2,5-oxadiazol-3-yl)-, N-(1,3,4-oxadiazol-2-yl)-, N-(tetrazol-5-yl)- and N-(triazol-5-yl)-aryl carboxamides, and use thereof as herbicides BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) 2020-03-31 US disclosed
EP-3356334-B1 ACYLATED N-(1,2,5-OXADIAZOL-3-YL)-, N-(1,3,4-OXADIAZOL-2-YL)-, N-(TETRAZOL-5-YL)- AND N-(TRIAZOL-5-YL)-ARYLCARBONIC ACID AMIDES AND THEIR USE AS HERBICIDES BAYER CROPSCIENCE AG (DE) 2019-12-18 EP disclosed
US-20180282290-A1 Acylated N-(1,2,5-oxadiazol-3-yl)-, N-(1,3,4-oxadiazol-2-yl)-, N-(tetrazol-5-yl)- and N-(triazol-5-yl)-aryl carboxamides, and use thereof as herbicides BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) 2018-10-04 US disclosed
EP-3356334-A1 ACYLATED N-(1,2,5-OXADIAZOLE-3-YL)-, N-(1,3,4-OXADIAZOLE-2-YL)-, N-(TETRAZOLE-5-YL)- AND N-(TRIAZOLE-5-YL)-ARYL CARBOXAMIDES, AND USE THEREOF AS HERBICIDES Bayer CropScience Aktiengesellschaft (DE) 2018-08-08 EP disclosed
EP-1751133-B1 COMPOSITIONS USEFUL AS INHIBITORS OF ROCK AND OTHER PROTEIN KINASES VERTEX PHARMA (US) 2010-04-14 EP disclosed
US-7531556-B2 Compositions useful as inhibitors of rock and other protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-05-12 US disclosed
EP-1751133-A2 COMPOSITIONS USEFUL AS INHIBITORS OF ROCK AND OTHER PROTEIN KINASES Vertex Pharmaceuticals Incorporated (US) 2007-02-14 EP disclosed
US-20060019956-A1 Compositions useful as inhibitors of rock and other protein kinases VERTEX PHARMACEUTICALS INCORPORATED 2006-01-26 US disclosed
WO-2005105780-A2 COMPOSITIONS USEFUL AS INHIBITORS OF ROCK AND OTHER PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2005-11-10 WO disclosed
EP-0641797-A1 Cephem derivatives and antimicrobial agents containing the same KATAYAMA SEIYAKUSYO CO. Ltd. (JP) 1995-03-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10604494-B2 Acylated N-(1 ,2,5-oxadiazol-3-yl)-, N-(1,3,4-oxadiazol-2-yl)-, N-(tetrazol-5-yl)- and N-(triazol-5-yl)-aryl carboxamides, and use thereof as herbicides NAT1, AADAC, ACOX3 PKM 2823/4885TP53 4739/4885NOTUM 407/4885
US-20060019956-A1 Compositions useful as inhibitors of rock and other protein kinases ROCK1, ROCK2, PRKCH PKM 759/4885TP53 589/4885NOTUM 2577/4885
US-20180282290-A1 Acylated N-(1,2,5-oxadiazol-3-yl)-, N-(1,3,4-oxadiazol-2-yl)-, N-(tetrazol-5-yl)- and N-(triazol-5-yl)-aryl carboxamides, and use thereof as herbicides NAT1, AADAC, ACOX3 PKM 2661/4885TP53 4665/4885NOTUM 414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.